<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35116073</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1748-6718</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2022</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Computational and mathematical methods in medicine</Title>
          <ISOAbbreviation>Comput Math Methods Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>G-Protein-Coupled Receptor Kinase-Interacting Protein 1 (GIT1) Promotes Head and Neck Squamous Cell Carcinoma Metastases via Activating the PI3K/AKT/mTOR Signal Pathway.</ArticleTitle>
        <Pagination>
          <StartPage>6881932</StartPage>
          <MedlinePgn>6881932</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">6881932</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/6881932</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">GIT1 is identified as a novel tumor oncogene in breast cancer. In this article, we aimed to explore the role of GIT1 in the progression of head and neck squamous cell carcinoma (HNSCC).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">GIT1 expression in HNSCC was detected by RT-qPCR, immunohistochemistry assay, and Western blot. HNSCC cell proliferation, migration, and invasion were examined by CCK-8 assay, Wound healing assay, and Transwell assay, respectively. Cell apoptosis was detected by flow cytometric analysis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In our study, GIT1 was notably upregulated in HNSCC tissues and cells. Moreover, GIT1 expression level had positive corelation with pathological grade and nodal status of HNSCC. Functional experiments showed that knockdown of GIT1 restrained HNSCC proliferation, invasion, migration, and EMT and facilitated cell apoptosis. Furthermore, GIT1 knockdown was found to restrain HNSCC tumor growth and lung metastasis. Additionally, PI3K/AKT/mTOR signal pathway inhibitors suppressed the effect of GIT1 on HNSCC cell progression.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">GIT1 was upregulated in HNSCC and facilitated HNSCC cell progression by inducing PI3K/AKT/mTOR signal pathway. Therefore, we suggested that GIT1 might be a potential target for HNSCC treatment.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022 Runze Xu et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Runze</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate School, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Ran</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Cancer Diagnosis and Treatment, JiangSu Rudong County People's Hospital, Nantong 226400, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yuanxiang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, JiangSu Rudong Country People's Hospital, Nantong 226400, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Weixing</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Cancer Diagnosis and Treatment, JiangSu Rudong County People's Hospital, Nantong 226400, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Lingling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Nursing, JiangSu Rudong Country People's Hospital, Nantong 226400, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Shishun</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6912-021X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Rehabilitation, Hainan Medical College, Haikou, 571199 Hainan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Comput Math Methods Med</MedlineTA>
        <NlmUniqueID>101277751</NlmUniqueID>
        <ISSNLinking>1748-670X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C485647">GIT1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35116073</ArticleId>
        <ArticleId IdType="pmc">PMC8807036</ArticleId>
        <ArticleId IdType="doi">10.1155/2022/6881932</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cohen N., Fedewa S., Chen A. Epidemiology and demographics of the head and neck cancer population. 
Oral and Maxillofacial Surgery Clinics of North America
. 2018;30(4):381â395. doi: 10.1016/j.coms.2018.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coms.2018.06.001</ArticleId>
            <ArticleId IdType="pubmed">30078696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verduci L., Ferraiuolo M., Sacconi A., et al.  The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. 
Genome Biology
. 2017;18(1):p. 237. doi: 10.1186/s13059-017-1368-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13059-017-1368-y</ArticleId>
            <ArticleId IdType="pmc">PMC5738800</ArticleId>
            <ArticleId IdType="pubmed">29262850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothenberg S. M., Ellisen L. W. The molecular pathogenesis of head and neck squamous cell carcinoma. 
Journal of Clinical Investigation
. 2012;122(6):1951â1957. doi: 10.1172/JCI59889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI59889</ArticleId>
            <ArticleId IdType="pmc">PMC3589176</ArticleId>
            <ArticleId IdType="pubmed">22833868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belcher R., Hayes K., Fedewa S., Chen A. Y. Current treatment of head and neck squamous cell cancer. 
Journal of Surgical Oncology
. 2014;110(5):551â574. doi: 10.1002/jso.23724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.23724</ArticleId>
            <ArticleId IdType="pubmed">25053506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knecht R. Aktuelle Therapiekonzepte bei Kopf-Hals-Tumoren. 
HNO
. 2015;63(9):p. 605. doi: 10.1007/s00106-015-0051-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00106-015-0051-4</ArticleId>
            <ArticleId IdType="pubmed">26319427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuang J., Zhao M., Li H., Dang W., Li W. Identification of potential therapeutic target genes and mechanisms in head and neck squamous cell carcinoma by bioinformatics analysis. 
Oncology Letters
. 2016;11(5):3009â3014. doi: 10.3892/ol.2016.4358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2016.4358</ArticleId>
            <ArticleId IdType="pmc">PMC4840659</ArticleId>
            <ArticleId IdType="pubmed">27123054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Artavanis-Tsakonas S., Rand M., Lake R. Notch signaling: cell fate control and signal integration in development. 
Science (New York, NY)
. 1999;284(5415):770â776. doi: 10.1126/science.284.5415.770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.284.5415.770</ArticleId>
            <ArticleId IdType="pubmed">10221902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pang J., Hoefen R., Pryhuber G., et al.  G-protein-coupled receptor kinase interacting protein-1 is required for pulmonary vascular development. 
Circulation
. 2009;119(11):1524â1532. doi: 10.1161/CIRCULATIONAHA.108.823997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.823997</ArticleId>
            <ArticleId IdType="pmc">PMC2732662</ArticleId>
            <ArticleId IdType="pubmed">19273721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louvi A., Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. 
Nature Reviews Neuroscience
. 2006;7(2):93â102. doi: 10.1038/nrn1847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn1847</ArticleId>
            <ArticleId IdType="pubmed">16429119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao S., Liu H., Chen J., et al.  Macrophage GIT1 contributes to bone regeneration by regulating inflammatory responses in anERK/NRF2âdependent way. 
Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
. 2020;35(10):2015â2031. doi: 10.1002/jbmr.4099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbmr.4099</ArticleId>
            <ArticleId IdType="pmc">PMC7689802</ArticleId>
            <ArticleId IdType="pubmed">32460388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong Y., Chang C., Liu J., Qiang J. Targeting of GIT1 by miR-149â in breast cancer suppresses cell proliferation and metastasis in vitro and tumor growth in vivo. 
Oncotargets and Therapy
. 2017;Volume 10:5873â5882. doi: 10.2147/OTT.S144280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S144280</ArticleId>
            <ArticleId IdType="pmc">PMC5729835</ArticleId>
            <ArticleId IdType="pubmed">29270025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J., Yang P., Yang J., Wen Z., Zhang B., Zheng X. GIT1 is a novel prognostic biomarker and facilitates tumor progression via activating ERK/MMP9 signaling in hepatocellular carcinoma. 
Oncotargets and Therapy
. 2015;8:3731â3742. doi: 10.2147/OTT.S96715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S96715</ArticleId>
            <ArticleId IdType="pmc">PMC4689273</ArticleId>
            <ArticleId IdType="pubmed">26719701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang W., Chan S., Jang T., et al.  miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis. 
Cancer Research
. 2014;74(3):751â764. doi: 10.1158/0008-5472.CAN-13-1297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-1297</ArticleId>
            <ArticleId IdType="pubmed">24335959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Morais E., Rolim L., de Melo Fernandes Almeida D., de Farias Morais H., de Souza L., de Almeida Freitas R. Biological role of epithelial-mesenchymal-transition-inducing transcription factors in head and neck squamous cell carcinoma: a systematic review. 
Archives of Oral Biology
. 2020;119, article 104904 doi: 10.1016/j.archoralbio.2020.104904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.archoralbio.2020.104904</ArticleId>
            <ArticleId IdType="pubmed">32947165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>di Cosimo S., Scaltriti M., Val D., et al.  The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. 
Journal of Clinical Oncology
. 2007;25(18_suppl):p. 3511. doi: 10.1200/jco.2007.25.18_suppl.3511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2007.25.18_suppl.3511</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts L. R., Gores G. J. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. 
Seminars in Liver Disease
. 2005;25(2):212â225. doi: 10.1055/s-2005-871200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2005-871200</ArticleId>
            <ArticleId IdType="pubmed">15918149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh S., Yap W., Arfuso F., et al.  Targeting the PI3K/Akt signaling pathway in gastric carcinoma: a reality for personalized medicine? 
World Journal of Gastroenterology
. 2015;21(43):12261â12273. doi: 10.3748/wjg.v21.i43.12261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v21.i43.12261</ArticleId>
            <ArticleId IdType="pmc">PMC4649111</ArticleId>
            <ArticleId IdType="pubmed">26604635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samarin J., Laketa V., Malz M., et al.  PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. 
Hepatology
. 2016;63(3):813â826. doi: 10.1002/hep.28357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28357</ArticleId>
            <ArticleId IdType="pmc">PMC5262441</ArticleId>
            <ArticleId IdType="pubmed">26901106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang S., Chen J., Lv B., et al.  Decreased long non-coding RNA lincFOXF1 indicates poor progression and promotes cell migration and metastasis in osteosarcoma. 
Journal of Cellular and Molecular Medicine
. 2020;24(21):12633â12641. doi: 10.1111/jcmm.15828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.15828</ArticleId>
            <ArticleId IdType="pmc">PMC7686999</ArticleId>
            <ArticleId IdType="pubmed">32945076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao L., Tong D., Xue M., et al.  MeCP2, a target of miR-638, facilitates gastric cancer cell proliferation through activation of the MEK1/2-ERK1/2 signaling pathway by upregulating GIT1. 
Oncogene
. 2017;6(7, article e368) doi: 10.1038/oncsis.2017.60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/oncsis.2017.60</ArticleId>
            <ArticleId IdType="pmc">PMC5541712</ArticleId>
            <ArticleId IdType="pubmed">28759023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z., Hu P., Xiong J., Wang S. Inhibiting GIT1 reduces the growth, invasion, and angiogenesis of osteosarcoma. 
Cancer Management and Research
. 2018;Volume 10:6445â6455. doi: 10.2147/CMAR.S181066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S181066</ArticleId>
            <ArticleId IdType="pmc">PMC6278701</ArticleId>
            <ArticleId IdType="pubmed">30555255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao W., Wang C., Sun Y., Su Y., Pang D., Zhang G. MicroRNA-34c suppresses breast cancer migration and invasion by targeting GIT1. 
Journal of Cancer
. 2016;7(12):1653â1662. doi: 10.7150/jca.14762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.14762</ArticleId>
            <ArticleId IdType="pmc">PMC5039386</ArticleId>
            <ArticleId IdType="pubmed">27698902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang J., Su C., Yu W., et al.  GIT1 promotes lung cancer cell metastasis through modulating Rac1/Cdc42 activity and is associated with poor prognosis. 
Oncotarget
. 2015;6(34):36278â36291. doi: 10.18632/oncotarget.5531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.5531</ArticleId>
            <ArticleId IdType="pmc">PMC4742177</ArticleId>
            <ArticleId IdType="pubmed">26462147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Chang Y., He X., et al.  CD47 enhances cell viability and migration ability but inhibits apoptosis in endometrial carcinoma cells via the PI3K/Akt/mTOR signaling pathway. 
Frontiers in Oncology
. 2020;10:p. 1525. doi: 10.3389/fonc.2020.01525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.01525</ArticleId>
            <ArticleId IdType="pmc">PMC7479237</ArticleId>
            <ArticleId IdType="pubmed">32984001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horn D., Hess J., Freier K., Hoffmann J., Freudlsperger C. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. 
Expert Opinion on Therapeutic Targets
. 2015;19(6):795â805. doi: 10.1517/14728222.2015.1012157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14728222.2015.1012157</ArticleId>
            <ArticleId IdType="pubmed">25652792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi M., Moon S., Lee S., et al.  Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells. 
Oncology Letters
. 2018;15(5):6489â6496. doi: 10.3892/ol.2019.10014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2019.10014</ArticleId>
            <ArticleId IdType="pmc">PMC5876434</ArticleId>
            <ArticleId IdType="pubmed">29616118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A. K., Mckenna W. G., Weber C. N., et al.  Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. 
Clinical Cancer Research An Official Journal of the American Association for Cancer Research
. 2002;8(3):885â892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11895923</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
